| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.59B | 27.10B | 28.33B | 36.25B | 25.96B |
| Gross Profit | 7.29B | 9.65B | 9.74B | 17.05B | 7.60B |
| EBITDA | 11.36B | 12.72B | 14.54B | 22.16B | 13.89B |
| Net Income | 2.37B | 3.04B | 4.67B | 13.22B | 2.31B |
Balance Sheet | |||||
| Total Assets | 86.78B | 85.44B | 74.01B | 72.61B | 75.04B |
| Cash, Cash Equivalents and Short-Term Investments | 1.99B | 2.13B | 1.43B | 984.00M | 2.76B |
| Total Debt | 23.96B | 27.10B | 20.91B | 20.77B | 30.39B |
| Total Liabilities | 50.19B | 50.97B | 43.66B | 42.52B | 54.71B |
| Stockholders Equity | 36.03B | 34.16B | 30.25B | 30.09B | 20.33B |
Cash Flow | |||||
| Free Cash Flow | 4.11B | 4.42B | 6.06B | 12.46B | 7.56B |
| Operating Cash Flow | 10.53B | 11.44B | 12.31B | 16.81B | 10.43B |
| Investing Cash Flow | -5.80B | -14.59B | -6.98B | -4.87B | -1.25B |
| Financing Cash Flow | -4.84B | 3.84B | -4.89B | -13.71B | -8.57B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $51.30B | 26.12 | 4.34% | 2.70% | 60.29% | -17.62% | |
79 Outperform | $71.68B | 11.37 | 16.76% | 3.79% | -5.15% | -19.06% | |
77 Outperform | $28.68B | 10.12 | 17.47% | 2.64% | 11.14% | -21.32% | |
74 Outperform | $24.41B | 11.67 | 11.77% | 3.39% | 26.13% | 31.42% | |
73 Outperform | $57.09B | 16.93 | 6.43% | 2.39% | -2.48% | -65.26% | |
73 Outperform | $41.32B | 10.87 | 7.67% | 6.85% | 15.31% | 58.83% | |
65 Neutral | $15.17B | 7.61 | 4.09% | 5.20% | 3.87% | -62.32% |
On March 5, 2026, Occidental announced early results of cash tender offers for multiple series of senior notes and debentures, alongside related consent solicitations to amend certain indenture terms. The company increased the maximum aggregate principal amount targeted in the offers from $700 million to $1.2 billion, fully subscribing the program by the early tender deadline on March 4, 2026 and triggering proration for the 6.625% 2030 Notes while excluding the 7.200% and 7.950% 2029 Debentures from early acceptance.
Occidental also confirmed that it had accepted all tendered Zero Coupon 2036 Notes and 6.125% 2031 Notes and secured the requisite consents to amend the 2019 indenture for the 6.125% 2031 Notes, with the supplemental indenture becoming operative on March 9, 2026. The amendments remove certain covenants and shorten redemption notice to five business days for that series, signaling a more flexible liability management framework that could lower funding costs and give the company greater optionality in future debt redemptions, while leaving indenture terms for the 2030 and 2029 issues unchanged due to insufficient consents.
The most recent analyst rating on (OXY) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on Occidental Petroleum stock, see the OXY Stock Forecast page.
On February 19, 2026, Occidental Petroleum launched cash tender offers to repurchase up to $700 million in aggregate principal amount of several series of its outstanding senior notes and debentures, including a $58 million sub-cap for its zero coupon notes due 2036, with an expiration date of March 19, 2026. The offers feature an early tender deadline of March 4, 2026, early tender premiums, and settlement dates shortly after each deadline, with funding to come from cash on hand, including proceeds from the January 2, 2026 sale of Occidental Chemical Corporation and its subsidiaries.
In conjunction with the tender offers, Occidental is soliciting consents from holders of most of the targeted notes to approve amendments that would remove certain covenants from the governing indentures, contingent on achieving requisite consent levels. The transaction is designed to reduce and reshape Occidental’s debt profile while loosening some bond covenant restrictions, signaling continued balance sheet management following the divestiture of its chemical business and potentially improving financial flexibility for the company and its stakeholders.
The most recent analyst rating on (OXY) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on Occidental Petroleum stock, see the OXY Stock Forecast page.
On January 2, 2026, Occidental completed the $9.7 billion all-cash sale of its chemical business, OxyChem, to Berkshire Hathaway, finalizing a divestiture first agreed in October 2025. The transaction is intended to accelerate Occidental’s strategy to strengthen its balance sheet and sharpen its focus on its higher-return oil and gas portfolio, while the company retains OxyChem’s legacy tort claims and certain environmental liabilities in a separate subsidiary that will continue funding and managing long-term remediation activities, a structure that preserves the operational value of the assets for the buyer while keeping historical risk obligations with Occidental.
The most recent analyst rating on (OXY) stock is a Hold with a $46.00 price target. To see the full list of analyst forecasts on Occidental Petroleum stock, see the OXY Stock Forecast page.